基础医学与临床 ›› 2012, Vol. 32 ›› Issue (9): 1093-1094.

• 研究短文 • 上一篇    下一篇

罗格列酮对2型糖尿病大鼠血清ox-LDL、ET、NO的干预作用

胡丽叶1,宋光耀2,朱旅云1,李晓玲1   

  1. 1. 中国人民解放军白求恩国际和平医院
    2. 河北省人民医院内分泌科
  • 收稿日期:2011-08-14 修回日期:2011-12-23 出版日期:2012-09-05 发布日期:2012-08-28
  • 通讯作者: 胡丽叶 E-mail:qianqianhu1998@163.com
  • 基金资助:
    不同糖耐量人群亚临床血管病变的早期检测及药物干预研究

Effect of rosiglitazone on serum changes of ox-LDL, ET and NO in type 2 diabetes rat.

  • Received:2011-08-14 Revised:2011-12-23 Online:2012-09-05 Published:2012-08-28
  • Contact: liye Hu E-mail:qianqianhu1998@163.com

摘要: 目的:制备2型糖尿病的动物模型,分析血清ox-LDL水平变化与ET、NO改变的关系,并了解罗格列酮的干预作用。方法:雄性Wistar大鼠80只,随机分为对照组、高脂组、糖尿病组、罗格列酮治疗组各20只,制备2型糖尿病大鼠模型,成模后罗格列酮治疗组予罗格列酮灌胃治疗,先后于灌胃治疗6周和12周时处死部分动物取血进行血糖、血脂、胰岛素、氧化型低密度脂蛋白(ox-LDL)、内皮素(ET)、一氧化氮(NO)的检测,比较各组间指标变化及各组自身前后的指标变化。结果:1 糖尿病成模后6周和12周,与对照组相比,罗格列酮治疗组、糖尿病组血糖、血脂、空腹胰岛素水平升高,p<0.05。罗格列酮治疗组12周时胰岛素水平较6周时下降,p<0.01。2 糖尿病成模后6周时:与对照组比较,高脂组、糖尿病组和罗格列酮治疗组ox-LDL升高,p<0.05。糖尿病成模后12周时:糖尿病组ox-LDL较对照组升高,p<0.01。高脂组12周时ox-LOX较6周时升高,p<0.01。3 糖尿病成模后6周和12周时,与对照组比较,高脂组、糖尿病组及罗格列酮治疗组ET升高,p<0.01。12周时糖尿病组较高脂组和罗格列酮治疗组ET升高,p<0.05。4 糖尿病成模后6周和12周时,与对照组比较,高脂组、糖尿病组及罗格列酮治疗组NO降低,p<0.01。12周时与高脂组和罗格列酮治疗组比较,糖尿病组NO降低,p<0.05。糖尿病组自身NO水平在12周时与6周时比较下降,p<0.05。结论:1 糖尿病组大鼠较高脂饮食组大鼠表现出更明显的糖脂代谢紊乱,且随时间延长程度加重。2 无论是糖尿病组还是高脂饮食组大鼠致动脉硬化因子ox-LDL、ET升高,预防动脉硬化的保护因子NO下降,并随时间延长有加重趋势。3 罗格列酮可一定程度改善T2DM大鼠的脂代谢紊乱、IR,降低AS致病因子ox-LDL、ET,改善NO/ET失衡。

关键词: 2型糖尿病, 大鼠, 氧化型低密度脂蛋白, 罗格列酮, 干预

Abstract: Objective: To develop a rat model with the metabolic abnormalities of type 2 diabetic mellitus. To study the changes of serum changes of ox-LDL, ET, NO and the relashionship among them. And to observe intervention effect of rosiglitazone. Methods: 80 male Wistar rats were randomized to control group, high fat diet group, diabetes group, and rosiglitazone treatment group (diabetes plus rosiglitazone treatment). Type 2 diabetes models were developed and rosiglization group was treated with rosiglitazone. After 6 weeks and 12 weeks of treatment with rosiglitazone, rats were sacrificed and blood sample were collected. Blood glucose, fat, insulin, oxided low density lipoprotein, endothlin and nitric oxide were tested. Data were compared among the four groups. Data of 6 week and 12 week were compared in each group itself. Results: 1. At 6 week and at 12 week, compared with control group, blood glucoses, lipid profile and fasting inuslin of high fat diet group, diabetes group and rosiglitazone group were increased significantly. 2. Compared with control group, ox-LDL in high fat diet group, diabetes group and rosiglitazone group increased significantly at 6 week. At 12 week, ox-LDL in diabetes group increased significantly than that of control group. Compared with that at 6 week, ox-LDL at 12 week in high fat diet group increased significantly. 3. Compared with control group, endothelin in high fat diet group, diabetes group and rosiglitazone group increased at 6 week and 12 week. And endothelin in diabetes group was higher than that in high fat diet group and rosiglitazone group at 12 week. 4. Compared with control group, nitric oxide in high fat diet group, diabetes group and rosiglitazone group decreased at 6 week and 12 week. And nitric oxide in diabetes group was lower than that in high fat diet group and rosiglitazone group at 12 week. Conclusion: 1. There are more aggravated glucose and lipid metabolic disorder in diabetes group than in high-fat diet group, and all of these are aggravated gradually with the prolongation of time. 2. Both in diabetes group and in high-fat group, the level of ox-LDL and endothelin are increased, while NO is decreased gradually with time prolongation. 3. Rosiglitazone can improve the glucose and lipid metabolic disorder and insulin resistance in type 2 diabetes rats in some degree. And it can also decrease the atherosclerosis factors, such as ox-LDL, ET, and correct the imbalance of NO/ET.

Key words: type 2 diabetes, rat, oxide low density lipoprotein, rosiglitazone, intervention